Difference between revisions of "Clear cell renal cell carcinoma"
| [unchecked revision] | [unchecked revision] |
| Line 26: | Line 26: | ||
== Genomic Gain/Loss/LOH == | == Genomic Gain/Loss/LOH == | ||
| − | + | {| class="wikitable sortable" | |
| + | |- | ||
| + | ! Chromosome !! Gain/Loss/Amp !! Region | ||
| + | |- | ||
| + | | 1 || Loss || 1p | ||
| + | |- | ||
| + | |3 || Loss || 3p (3p21, 3p25 and/or 3p13-p14) | ||
| + | |- | ||
| + | |4 || Loss || 4q | ||
| + | |- | ||
| + | |5 || Gain || 5q | ||
| + | |- | ||
| + | |8 || Loss || 8p | ||
| + | |- | ||
| + | |9 || Loss || 9p, 9q | ||
| + | |- | ||
| + | |14 ||Loss || 14q | ||
| − | + | |} | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
== Rearrangements == | == Rearrangements == | ||
Revision as of 20:49, 12 February 2016
Contributors
Daynna Wolff PhD FACMG
Tumor Type
Renal Cell Carcinoma
Tumor Classification
Clear Cell RCC
This tumor type accounts for 70-75% of all renal cell carcinoma cases (citation needed).
Description
Malignant epithelial cells with clear cytoplasm and a compact-alveolar (nested) or acinar growth pattern interspersed with intricate, arborizing vasculature. A variable proportion of cells with granular eosinophilic cytoplasm may be present. Infrequently, clear cell renal cell carcinoma has a distinct tubular pattern and rarely a pseudopapillary architecture is focally present."
IHC Markers
Positive: vimentin, CD10, RCC, PAX2, PAX8, CA-IX, EMA
Negative: CK7, CD117, AMACR, E-cadherin
Genomic Gain/Loss/LOH
| Chromosome | Gain/Loss/Amp | Region |
|---|---|---|
| 1 | Loss | 1p |
| 3 | Loss | 3p (3p21, 3p25 and/or 3p13-p14) |
| 4 | Loss | 4q |
| 5 | Gain | 5q |
| 8 | Loss | 8p |
| 9 | Loss | 9p, 9q |
| 14 | Loss | 14q |
Rearrangements
Write your comments here
Mutations (SNV/INDEL)
Write your comments here
From Cosmic Mutated in >20%
Mutated in 10-20%
Mutated in 5-10%
Mutated in 2-5%
mtDNA
Epigenomics (methylation)
Write your comments here
Main Pathways Involved
Write your comments here
Clinical Significance
Write your comments here
Diagnosis
Write your comments here
Prognosis
Write your comments here
Therapeutics
Write your comments here
Familial Forms
Write your comments here